stockrow
Friday 6 November 2026
Export ELVN’s income statement to Excel — free account
Enliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
48.63
3.84
+8.57%
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) Current ratio
Enliven Therapeutics, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 64.1×, up 35.4× from fiscal 2025 (28.7×). Over the past ten years it has ranged from 4.2× (fiscal 2018) to 28.7× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 28.7× | 43.39% |
| FY2024 | 20.0× | 94.47% |
| FY2023 | 10.3× | 28.43% |
| FY2022 | 8.0× | (37.75%) |
| FY2021 | 12.9× | (11.16%) |
| FY2020 | 14.5× | 98.38% |
| FY2019 | 7.3× | 73.45% |
| FY2018 | 4.2× | (66.02%) |
| FY2017 | 12.4× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 64.1× | 58.92% |
| Mar 2026 | 40.3× | 40.67% |
| Dec 2025 | 28.7× | (13.01%) |
| Sep 2025 | 32.9× | 1.12% |
| 23 more quarters | Free account |
Against its own ten years
Low 4.2×
High 28.7×
Ten-year median
12.4×
Current reading's percentile
100
Current ratio against peers
| Company | Current ratio |
|---|---|
| ELVN Enliven Therapeutics, Inc. | 64.1× |
| VRDN Viridian Therapeutics, Inc. compare | 14.5× |
| DYN Dyne Therapeutics, Inc. compare | 12.0× |
| CELC Celcuity, Inc. compare | 8.9× |
| VKTX Viking Therapeutics, Inc. compare | 7.3× |
| DNLI Denali Therapeutics Inc. compare | 6.2× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 3.8× |
| TLX Telix Pharmaceuticals Limited compare | 2.0× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.0× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)